The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...

Dr. Calabrese answers the question: 'When Can I Stop Taking Bipolar Meds?' — -- Question: How long do I have to take medication for bipolar disorder, and can I stop if I no longer have symptoms?

Bipolar disorder is a mental health condition that causes significant and sudden changes in mood that involve episodes of mania and sometimes depression. There is no cure for bipolar disorder, so ...

Dr. Calabrese answers the question: 'What If I Refuse Bipolar Medications?' — -- Question: What if I choose not to use medications for bipolar disorder? Answer: Now one of our most challenging ...

This new blog column aims to provide a “deep dive” into the science-backed, therapeutic skills that can help people with bipolar disorder lead healthy and enriched lives. Mood-stabilizing medication ...

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Trisha Suppes, MD, ...

Bipolar disorder exists on a spectrum rather than as a single, uniform condition. This fundamental characteristic explains why two people with the same diagnosis can experience dramatically different ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb Company is ...

A new study identifies specific brain regions involved in treatment response in bipolar disorder (BD) and borderline personality disorder (BPD), potentially paving the way for more targeted treatment.

Results from the largest and longest study of its kind have found that the drug metformin can help manage weight gain in ...

NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...